Navigation Links
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Medical Mutual
Date:12/23/2013

MINNEAPOLIS, Dec. 23, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Medical Mutual has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.  Medical Mutual is a large, regional private insurer with approximately 2.7 million covered lives, primarily in Ohio, as well as Georgia, Indiana, Michigan, Pennsylvania, South Carolina and West Virginia.

"This new policy reflects our continuing efforts to educate payers on the clinical benefits and cost effectiveness of Urgent PC therapy," said Nancy Kolb, Vice President of Healthcare Policy and Reimbursement.  "With the addition of Medical Mutual, we now have approximately 108 million lives covered by private payers and 40 million Medicare beneficiaries with access to Urgent PC therapy."

The policy is available on the Medical Mutual site at medicalmutual.com.

About Overactive Bladder

Overactive bladder (OAB) is a chronic condition that affects approximately 34 million US adults.  The symptoms include urinary urgency, frequency and urge incontinence.  The Urgent PC Neuromodulation System is the only FDA cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy. 

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical company committed to offering transformative treatment options to specialty physicians.  Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information
This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.

For Further Information:


Uroplasty, Inc.

Rob Kill

President and CEO

952.426.6140

EVC Group

Leigh Salvo (Investors)

415.568.9349

Janine McCargo (Media)

646.688.0425


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Names David B. Perry Vice President Of Marketing
2. Uroplasty Provides Update On PTNS Reimbursement
3. Uroplasty To Participate In The Piper Jaffray Healthcare Conference
4. Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Humana, Inc.
5. Uroplasty Sets New Quarterly Revenue Record During Fiscal Second Quarter 2014
6. Uroplasty To Participate In The Craig-Hallum Alpha Select Conference
7. Class Action Lawsuit Against Uroplasty Dismissed
8. Uroplasty Appoints Brett Reynolds As Chief Financial Officer
9. Uroplasty Reports Fiscal First Quarter 2014 Financial Results
10. Uroplasty Completes Internal Control Review; Files Form 10-K for Fiscal 2013
11. Uroplasty Announces Delay in Filing Form 10-K
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
Breaking Medicine News(10 mins):